Fmr LLC Karyopharm Therapeutics Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Karyopharm Therapeutics Inc. stock. As of the latest transaction made, Fmr LLC holds 293,213 shares of KPTI stock, worth $216,977. This represents 0.0% of its overall portfolio holdings.

Number of Shares

293,213

Previous 273,808 7.09%

Holding current value

$216,977

Previous $413,000 38.26%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.87 - $1.58 $16,882 - $30,659	19,405 Added 7.09%	293,213 $255,000
Q1 2024 May 13, 2024	BUY	$0.72 - $1.66 $3,975 - $9,166	5,522 Added 2.06%	273,808 $413,000
Q4 2023 Feb 13, 2024	BUY	$0.68 - $1.31 $1,250 - $2,409	1,839 Added 0.69%	268,286 $230,000
Q3 2023 Nov 13, 2023	BUY	$1.14 - $1.81 $405 - $644	356 Added 0.13%	266,447 $357,000
Q2 2023 Aug 11, 2023	BUY	$1.79 - $4.59 $270,476 - $693,567	151,104 Added 131.41%	266,091 $476,000
Q1 2023 May 11, 2023	BUY	$2.84 - $3.92 $11,547 - $15,938	4,066 Added 3.67%	114,987 $447,000
Q4 2022 Feb 13, 2023	SELL	$2.48 - $5.93 $2,909 - $6,955	-1,173 Reduced 1.05%	110,921 $377,000
Q3 2022 Nov 10, 2022	SELL	$4.08 - $5.82 $1,725 - $2,461	-423 Reduced 0.38%	112,094 $612,000
Q2 2022 Aug 12, 2022	SELL	$4.15 - $8.37 $6,038 - $12,178	-1,455 Reduced 1.28%	112,517 $507,000
Q1 2022 May 13, 2022	BUY	$5.91 - $14.38 $673,574 - $1.64 Million	113,972 New	113,972 $840,000
Q3 2021 Nov 15, 2021	SELL	$4.45 - $10.63 $8 - $21	-2 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$8.11 - $11.11 $16 - $22	2 New	2 $0

Others Institutions Holding KPTI

# of Institutions

120

Shares Held

64.9M

Call Options Held

500K

Put Options Held

99K

View Full List

About Karyopharm Therapeutics Inc.

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $59.1M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

More about KPTI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account